OncoMatch/Clinical Trials/NCT05989204
TmCD19-IL18 in CD19+ Cancers
Is NCT05989204 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TmCD19-IL18 for non hodgkin lymphoma.
Treatment: TmCD19-IL18 — This is a Phase I, open-label dose finding study to assess the safety and feasibility, pharmacokinetics, and preliminary efficacy of TmCD19-IL18 CAR T cells in patients with CD19+ cancers. This study will take place in two parts: a Dose-Finding Phase to determine the maximum tolerate dose (MTD), followed by a Dose Expansion Phase. In the Dose-Finding Phase, dose levels will be evaluated using a 3+3 dose escalation design to determine the MTD. Cumulative safety experience and manufacturing feasibility data from the Dose-Finding Phase will then be used to identify the dose level that can be progressed into the Dose Expansion Phase.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 expression (positive)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: CAR T cell therapy — relapsed/refractory or ineligible
Patients must have either relapsed after, or be ineligible for, prior CAR T cell therapy
Cannot have received: huCART19-IL18 therapy
Receipt of prior huCART19-IL18 therapy
Lab requirements
Kidney function
Estimated creatinine clearance > 35 mL/min and not on dialysis
Liver function
ALT/AST 3x upper limit of normal range; Direct bilirubin 2.0 mg/dl, unless the subject has Gilbert's syndrome ( 3.0 mg/dl)
Cardiac function
Left Ventricle Ejection Fraction (LVEF) 40% confirmed by ECHO
Adequate organ function defined as: Estimated creatinine clearance > 35 mL/min and not on dialysis; ALT/AST 3x upper limit of normal range; Direct bilirubin 2.0 mg/dl, unless the subject has Gilbert's syndrome ( 3.0 mg/dl); Must have a minimum level of pulmonary reserve defined as Grade 1 dyspnea and pulse oxygen > 92% on room air; Left Ventricle Ejection Fraction (LVEF) 40% confirmed by ECHO
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify